Biotech Effectiveness: Horizon Pharma (HZNP)
Post# of 150
Posted On: 03/08/2015 11:05:02 PM
Horizon Pharma plc (HZNP) said that pre-clinical data from an investigator initiated study demonstrated that treatment with murine interferon gamma, which is an analogue of interferon gamma-1b (ACTIMMUNE(R)), improved the signs of disease severity in a mouse model of Autosomal Dominant Osteopetrosis Type II, the most common form of osteopetrosis, a group of conditions characterized by an increased skeletal mass due to impaired bone and cartilage resorption.
HZNP's ACTIMMUNE, a biologically manufactured protein similar to one the body makes naturally to help prevent infection, is currently FDA-approved for use in two rare diseases. It is indicated to reduce the frequency and severity of serious infections associated with Chronic Granulomatous Disease, a genetic disorder that affects the functioning of some cells of the immune system. In addition, HZNP's ACTIMMUNE is indicated to slow the worsening of severe, malignant osteopetrosis, a genetic disorder that affects normal bone formation.
Shares of HZNP surged $1.07 (or +5.11%) to $21.91 on Friday's trading session
HZNP is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs
More about Horizon Pharma plc (HZNP) at www.horizonpharma.com
**
Zafgen, Inc. (ZFGN) reported positive efficacy and safety data from a recently completed Phase 2 trial of beloranib, a MetAP2 inhibitor, in patients with hypothalamic injury associated obesity, a rare form of medically induced obesity resulting from damage to the hypothalamus following resection of central nervous system tumors such as craniopharyngiomas
According to ZFGN, the results from this trial demonstrated meaningful and statistically significant weight loss and improvement in cardiometabolic biomarkers
ZFGN's beloranib is a novel, first-in-class injectable small molecule therapy with a unique mechanism of action that reduces hunger while stimulating the use of stored fat as an energy source.
ZFGN stock closed at $38.75 on Friday, down $0.45 (or -1.15%).
ZFGN is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders.
More about Zafgen, Inc. (ZFGN) at www.zafgen.com
**
XOMA Corp. (XOMA) announced positive data from XOMA 358, the lead antibody in the Company's XMet D program.
According to XOMA, results from the Phase 1 first-in-human study show XOMA 358 reduces insulin receptor signaling and increased glucose production after exogenous insulin injection
These preliminary data provide a strong rationale for continued study of XOMA 358 in adults and children with hypoglycemia due to overproduction of insulin.
XOMA 358 is a fully human allosteric modulating monoclonal antibody that binds to insulin receptors and attenuates insulin action
XOMA plans to release its fourth quarter and full year 2014 financial results on Wednesday, March 11, 2015.
On Friday, the price of XOMA stock declined $0.09 (or -2.33%) to $3.57 per share
XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies.
More about XOMA Corp. (XOMA) at www.xoma.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Redding, CA ( www.redding.crwe-pr.com ) into the CRWE Network.
Redding is the county seat of Shasta County, California. It is centrally located in the Shasta-Cascade region at the top of the Sacramento Valley in far northern California.
The City of Redding had an estimated population in 2013 (U.S. Census Bureau) of 91,119, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
HZNP's ACTIMMUNE, a biologically manufactured protein similar to one the body makes naturally to help prevent infection, is currently FDA-approved for use in two rare diseases. It is indicated to reduce the frequency and severity of serious infections associated with Chronic Granulomatous Disease, a genetic disorder that affects the functioning of some cells of the immune system. In addition, HZNP's ACTIMMUNE is indicated to slow the worsening of severe, malignant osteopetrosis, a genetic disorder that affects normal bone formation.
Shares of HZNP surged $1.07 (or +5.11%) to $21.91 on Friday's trading session
HZNP is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs
More about Horizon Pharma plc (HZNP) at www.horizonpharma.com
**
Zafgen, Inc. (ZFGN) reported positive efficacy and safety data from a recently completed Phase 2 trial of beloranib, a MetAP2 inhibitor, in patients with hypothalamic injury associated obesity, a rare form of medically induced obesity resulting from damage to the hypothalamus following resection of central nervous system tumors such as craniopharyngiomas
According to ZFGN, the results from this trial demonstrated meaningful and statistically significant weight loss and improvement in cardiometabolic biomarkers
ZFGN's beloranib is a novel, first-in-class injectable small molecule therapy with a unique mechanism of action that reduces hunger while stimulating the use of stored fat as an energy source.
ZFGN stock closed at $38.75 on Friday, down $0.45 (or -1.15%).
ZFGN is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders.
More about Zafgen, Inc. (ZFGN) at www.zafgen.com
**
XOMA Corp. (XOMA) announced positive data from XOMA 358, the lead antibody in the Company's XMet D program.
According to XOMA, results from the Phase 1 first-in-human study show XOMA 358 reduces insulin receptor signaling and increased glucose production after exogenous insulin injection
These preliminary data provide a strong rationale for continued study of XOMA 358 in adults and children with hypoglycemia due to overproduction of insulin.
XOMA 358 is a fully human allosteric modulating monoclonal antibody that binds to insulin receptors and attenuates insulin action
XOMA plans to release its fourth quarter and full year 2014 financial results on Wednesday, March 11, 2015.
On Friday, the price of XOMA stock declined $0.09 (or -2.33%) to $3.57 per share
XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies.
More about XOMA Corp. (XOMA) at www.xoma.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Redding, CA ( www.redding.crwe-pr.com ) into the CRWE Network.
Redding is the county seat of Shasta County, California. It is centrally located in the Shasta-Cascade region at the top of the Sacramento Valley in far northern California.
The City of Redding had an estimated population in 2013 (U.S. Census Bureau) of 91,119, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
(0)
(0)